CD4-positive alpha-beta T cell (CD4+ T cell)

CD4-positive alpha-beta T cells are a major subset of T lymphocytes essential for adaptive immunity. They express the CD4 surface marker and alpha-beta T cell receptor, recognize antigens in the context of MHC class II molecules presented by antigen-presenting cells, and differentiate into multiple helper and regulatory subsets depending on the cytokine environment. Upon activation, they coordinate and amplify immune responses via cytokine secretion, helping activate B cells, cytotoxic T cells, and innate immune cells. The activation process integrates T cell receptor signaling, co-stimulatory interactions, and metabolic reprogramming governed by pathways such as PI3K/Akt/mTOR and AMPK. Defects in activation or regulation underlie multiple disease states, including immunodeficiency, autoimmunity, infection, and cancer. Drugs targeting co-stimulatory pathways (e.g., CTLA-4, CD28) and signaling cascades are used to modulate CD4+ T cell activation in therapy. The query "CD4-positive, alpha-beta T cell activation" is not a standard name for a therapeutic target; it denotes a cellular process. The correct target name is "CD4-positive alpha-beta T cell" or "CD4+ T cell." The activation pathway involves many molecular targets (CD4, TCR, CD3, CD28, CTLA-4), but "activation" itself is not a single molecule or receptor.

Other names

T helper cellTh cellCD4+ T cellCD4-positive T cell

Inhibition or modulation of co-stimulatory signals (e.g., blocking CD28-CD80/86 interaction). Checkpoint blockade (e.g., inhibiting CTLA-4 to enhance activation). Blocking intracellular signaling pathways (e.g., via PI3K/Akt/mTOR inhibitors). Direct depletion or functional suppression of CD4+ T cells.